Wells Fargo’s NovoCure NVCR Stock Holding History

Wells Fargo’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.85M	Hold	170,000	–	–	﹤0.01%	3331
2025 Q4	$2.2M	Buy	170,000 +120,000	+240%	+$1.54M	﹤0.01%	3354
2025 Q3	$646K	Hold	50,000	–	–	﹤0.01%	4112
2025 Q2	$890K	Hold	50,000	–	–	﹤0.01%	3768
2025 Q1	$891K	Buy	+50,000	New	+$1.14M	﹤0.01%	3719
2020 Q2	–	Sell	-35,800	Closed	-$23K	–	6646
2020 Q1	$23K	Buy	+35,800	New	+$2.83M	﹤0.01%	5567

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's NVCR Position: Q1 2026 in Review

Wells Fargo increased its NovoCure (NVCR) stake by 1,996% in Q1 2026, buying an estimated $35.1M and bringing the position to 2,951,237 shares worth $32.2M. The position accounts for 0.01% of the portfolio, ranked #1215.

Wells Fargo first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $197M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Wells Fargo held 2,951,237 shares of NovoCure worth $32.2M as of Q1 2026.
Wells Fargo bought 2,810,424 NovoCure shares in Q1 2026, an estimated $35.1M.
NovoCure made up 0.01% of Wells Fargo's portfolio in Q1 2026, its #1215 holding.
Wells Fargo first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
Wells Fargo's NovoCure position peaked at $197M in Q4 2020.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.